🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "major milestone" in the fight against superbug strains of the pathogen, according to scientists.

A Global Challenge

The sexually transmitted infection are escalating globally, with figures suggesting over 82 million infections each year. Notably increased rates are seen in the African continent and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an important and timely step in the reality of increasing worldwide cases, escalating drug resistance and the very limited therapeutic options presently on offer.”

Health officials are deeply concerned about the rise in antibiotic-resistant strains. The WHO has designated it as a "priority pathogen". A tracking program found that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Treatment Options Gain Authorization

One new antibiotic, alternatively called Nuzolvence, was approved by the American regulatory agency in mid-December for combating gonorrhoea. This STI can lead to serious health problems, including infertility. Experts believe that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the drugmaker GlaxoSmithKline, gained clearance in the same week. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin emerged from a unique collaborative effort for antibiotic development. The charitable organization GARDP worked alongside the pharmaceutical company its industry partner to see it through.

“This authorization signifies a significant shift in the therapy of superbug gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Testing Data and Worldwide Availability

According to data detailed in a major medical journal, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the current standard treatment, which combines two antibiotics. The study included hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the ability to make available and distribute the drug in a wide range of low-income and middle-income countries.

Medical professionals on the front lines have shared optimism. Access to a one-pill regimen like this is seen as a "critical tool" for gonorrhoea control. This is viewed as crucial to reduce the burden of the illness for people and to prevent the spread of untreatable gonorrhoea globally.